Tandem autologous hematopoietic stem cell transplantation (auto-auto) has been studied as a method of increasing remission rates and reducing relapse in the upfront treatment of multiple myeloma (MM).
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly approved agent for allogeneic hematopoietic stem cell transplantation (allo-HSCT) ...
Mikkael A. Sekeres, MD, of Sylvester Comprehensive Cancer Center, University of Miami, discussed data supporting the FDA approval of treosulfan as part of conditioning for allogeneic hematopoeitic ...
Findings from cohort 2 showed SER-155 reduced the relative risk of bacterial BSIs by 77% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced that the US Food and Drug ...
Phase 3 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in patients with essential thrombocythemia (ET). CLAMP: A phase II prospective study of camrelizumab combined with ...
Please provide your email address to receive an email when new articles are posted on . Treatment outcomes have improved significantly with both auto- and allo-HSCT over the past 3 decades. Both ...
LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results